Drug class in one race
Estrogen receptor drugs for HR+/HER2- Metastatic Breast Cancer
8 tracked Estrogen receptor drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the Estrogen receptor page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
5 approved / phase 43 Phase 3
Head-to-head evidence: Camizestrant vs Elacestrant · Camizestrant vs Fulvestrant · Camizestrant vs Giredestrant · Camizestrant vs Imlunestrant · Camizestrant vs Palazestrant · Camizestrant vs Vepdegestrant